Bank of Nova Scotia Takes Position in Edwards Lifesciences Corporation $EW

Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000.

Several other hedge funds also recently made changes to their positions in EW. BlackRock Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences in the second quarter worth about $1,274,082,000. Norges Bank bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $803,686,000. Deutsche Bank AG bought a new position in shares of Edwards Lifesciences in the second quarter worth about $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.5%

Shares of EW opened at $90.92 on Wednesday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a market cap of $52.35 billion, a PE ratio of 52.25, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $89.35 and a 200 day moving average of $84.82.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company's quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company's stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company's stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 2,425 shares of company stock valued at $219,199. 0.31% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Piper Sandler restated an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Evercore reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Citigroup increased their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source